News Release
News Release
June 16,2021
Announcing the Start of Phase III Clinical Trials for Functional Peptide SR-0379 [PDF file]
June 1,2021
January 29,2021
Announcement of Newly Developed Antibody-inducing Peptide Compound [PDF file]
December 25,2020
Announcement of New Listing on Tokyo Stock Exchange’s Mothers [PDF file]
April 8,2020
AnGes and Osaka University to Jointly Develop DNA Vaccine for COVID-19 [PDF file]
December 10,2019
Publication of Antibody-inducing Peptide Technology [PDF file]
April 17,2019
Initiation of Phase I-IIa Clinical Trial of Antibody-inducing Peptide FPP003 [PDF file]
February 18,2019
Shionogi and FunPep Conclude Joint Research Agreement on Antibody-Inducing Peptides [PDF file]
June 5,2018
Submission of a Phase II Clinical Trial Plan for Functional Peptide SR-0379 [PDF file]
April 9,2018
Announce of Conclusion of Option Agreement with Sumitomo Dainippon Pharma [PDF file]